Case report: Combination therapy of envafolimab with endostar for advanced non-small cell lung cancer with low PD-L1 expression.

Front Oncol · 2024 · PMC11578815 · PMID 39575420

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In this particular case, the patient’s progression-free survival (PFS) was 1.7 months longer than the median PFS observed in the NCT0362852 clinical trial, although this comparison did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.